Chronic Kidney Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 years or older.
• People with end-stage kidney disease who have been receiving intermittent hemodialysis (kidney dialysis) for more than 3 months before the screening visit, with each dialysis session lasting at least 4 hours.
• People whose dialysis sessions have been effectively managed with blood-thinning medication (either UFH or LMWH), with no loss of the dialysis circuit in the last 3 months.
• People whose dialysis is working adequately, as measured by a standard test called Kt/V, with an average result of 1.2 or higher.
• People whose blood calcium levels are within the normal range (2.2 to 2.6 mmol/L), based on the most recent monthly blood test.
• People who are enrolled in or covered by a social security system.
• People who have signed a written consent form agreeing to take part in the study.

Who may not be able to join:

• People whose dialysis access point (the entry point used for dialysis) is not working properly at the time of screening.
• People who use a single needle for their dialysis access (called unipuncture of the AVF).
• People currently receiving hemofiltration or hemodiafiltration (other types of kidney filtering treatments, different from standard hemodialysis).
• People currently taking ongoing blood-thinning (anticoagulation) medication outside of dialysis.
• People currently being treated with digitalis-based heart medications (a specific type of heart drug).
• People currently taking thiazide diuretics (a type of water tablet used to reduce fluid).
• People with high calcium levels in the blood or urine (hypercalcemia or hypercalciuria).
• People with a known history of allergy to heparin or a condition called heparin-induced thrombocytopenia (a serious reaction to heparin that affects blood platelets).
• People with active bleeding.
• People considered at high risk of bleeding, including those who have had bleeding, surgery, a head injury, or an ischemic stroke (a type of stroke caused by a blood clot) within the past 7 days, or who have a condition called uremic pericarditis (inflammation around the heart related to kidney disease).
• People whose body weight is below 45 kg or above 140 kg at screening.
• People with a known allergy to citrate.
• People who are in hospital at the time of screening for any reason other than their regular dialysis.
• People whose health is so critical that death is expected within three months.
• People with liver failure, based on their most recent blood test results (confirm with trial site for exact threshold used).
• People currently participating in another clinical trial involving dialysis or blood-thinning treatments.
• People who are pregnant or breastfeeding, and other groups with special legal protections under French health law, including people under legal guardianship, people hospitalised without their consent, people in social or health care facilities for treatment rather than research, and people in emergency situations.
• People who are unable or unwilling to give informed consent to take part in the study.
• People whose current dialysis prescription uses a heparin-coated membrane (a special type of dialysis filter treated with heparin).

Important: Always verify eligibility with the trial site directly before applying.